PEPTIDE COMPARISON

Epitalon vs MOTS-c

Two longevity-market peptides compared by verifiable human evidence rather than anti-aging narratives.

QUICK ANSWER

Epitalon vs MOTS-c: the main difference.

Neither peptide has evidence that supports broad longevity claims. MOTS-c has a clearer endogenous physiology literature; that still does not establish injected MOTS-c as a therapy.

Decision field	Epitalon	MOTS-c
Human research	Very limited and difficult to verify	Small endogenous-physiology studies
Primary research	Aging biology and gene-expression models	Mitochondrial signaling and exercise physiology
FDA status	Not approved	Not approved; no identified human exposure data for drug products
Main evidence gap	Modern confirmatory trials	Evidence for exogenous therapeutic use
Evidence confidence	Very low	Very low for treatment claims

SOURCES

Epitalon vs MOTS-c sources.

Review / 2025Epitalon: structural, physicochemical, and biological research reviewPubMed Government / 2023Compounding pharmacy plea involving unlawful unapproved drug distributionU.S. Department of Justice WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Preclinical / 2021MOTS-c and age-dependent physical declineNature Communications / PubMed Human trial / 2021Circulating mitochondrial-derived peptides after exercisePubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA

Epitalon vs MOTS-c: the main difference.

Epitalon vs MOTS-c sources.

Questions related to Epitalon vs MOTS-c.

Compare the next decision.